Daily Cosmetic Research Analysis
Three studies advance cosmetic and aesthetic medicine: a randomized split-face trial shows adjunctive intradermal botulinum toxin A improves melasma control alongside triple-combination cream; a multicenter blinded split-face RCT demonstrates a hyaluronic acid filler (saypha/Princess FILLER Lidocaine) is non-inferior to Juvéderm Ultra XC for nasolabial folds; and an anatomical-histological study indicates orbital fat has superior vascularity and graft survival characteristics versus subcutaneous
Summary
Three studies advance cosmetic and aesthetic medicine: a randomized split-face trial shows adjunctive intradermal botulinum toxin A improves melasma control alongside triple-combination cream; a multicenter blinded split-face RCT demonstrates a hyaluronic acid filler (saypha/Princess FILLER Lidocaine) is non-inferior to Juvéderm Ultra XC for nasolabial folds; and an anatomical-histological study indicates orbital fat has superior vascularity and graft survival characteristics versus subcutaneous fat, informing upper eyelid augmentation.
Research Themes
- Adjunctive neuromodulation for pigmentary disorders
- Comparative effectiveness of dermal fillers
- Surgical anatomy and graft biology for oculoplastic correction
Selected Articles
1. Efficacy of Botulinum Toxin A for the Management of Melasma: A Split-Face, Randomized Control Study.
In a randomized split-face trial of 30 women (28 completers), adding intradermal incoBoNT-A to triple-combination cream improved clinical melasma outcomes versus topical therapy alone and helped prevent recurrence through 24 weeks. Serial assessments indicated superior MASI-based improvement on the combination side.
Impact: This is controlled human trial evidence supporting a novel adjunctive use of botulinum toxin A for melasma, a condition with limited durable options.
Clinical Implications: Consider intradermal BoNT-A as an adjunct to triple-combination topical therapy for recurrent or refractory melasma, with counseling on off-label use and need for maintenance.
Key Findings
- Randomized split-face design with 30 female participants; 28 completed 24 weeks.
- Combination therapy (TCC + intradermal incoBoNT-A at baseline and week 12) yielded superior MASI-based improvement versus TCC alone.
- The combination regimen helped prevent melasma recurrence through 24 weeks.
Methodological Strengths
- Split-face randomization reduces inter-individual variability.
- Multiple scheduled assessments out to 24 weeks with standardized topical regimen.
Limitations
- Small single-center sample with only female participants.
- Blinding and full MASI/melanin index details are not specified in the abstract.
Future Directions: Larger multicenter RCTs with diverse populations, blinded assessments, dose-optimization, mechanistic endpoints (vascular/neuropeptide markers), and durability beyond 6–12 months.
BACKGROUND: Melasma management remains challenging due to its multifactorial nature pathogenesis and recurrent nature. Previous studies showed positive effects of botulinum toxin A (BoNT-A) for treating and preventing ultraviolet-induced hyperpigmentation. OBJECTIVE: To evaluate the effectiveness of adjunctive incoBoNT-A injection combined with triple combination cream (TCC, 4% hydroquinone, 0.05% tretinoin, and 0.01% fluocinolone acetonide) for treating and preventing melasma recurrence compared to topical therapy alone. METHODS: A split-face study was conducted in 30 female pat
2. Multicenter, Randomized Split-Face Trial of a Crosslinked Hyaluronic Acid Filler With Lidocaine for Nasolabial Fold Correction.
In a blinded multicenter split-face RCT, saypha/Princess FILLER Lidocaine achieved non-inferiority to Juvéderm Ultra XC for nasolabial fold correction at week 24 (82.2% vs 81.9% responders). Safety profiles and patient-reported outcomes (FACE-Q, GAIS) were comparable, with mostly mild-to-moderate adverse events.
Impact: Provides robust comparative effectiveness and safety data between widely used hyaluronic acid fillers, informing product selection and patient counseling.
Clinical Implications: saypha/Princess FILLER Lidocaine can be considered an alternative to Juvéderm Ultra XC for moderate-to-severe nasolabial folds, with similar efficacy, safety, and satisfaction over up to 48 weeks.
Key Findings
- Non-inferiority at week 24: 82.2% vs 81.9% NLF-SRS responders (difference 0.37%, p < 0.0001).
- Blinded multicenter split-face design with assessments by investigators, photographic reviewers, GAIS, and FACE-Q.
- Adverse events after PFL in 24.4% of subjects, mostly mild-to-moderate; serious TEAEs were rare (1.1%).
Methodological Strengths
- Randomized, subject- and investigator-blinded split-face design minimizes bias.
- Validated outcome measures (NLF-SRS, GAIS, FACE-Q) with follow-up to 48 weeks and safety monitoring.
Limitations
- Exact sample size not stated in abstract; non-inferiority design may not detect small superiority differences.
- Split-face filler studies may risk unblinding due to injection characteristics despite blinding efforts.
Future Directions: Head-to-head cost-effectiveness analyses, real-world durability beyond 1 year, and surveillance of delayed adverse events (nodules, Tyndall effect, vascular complications).
BACKGROUND: Nasolabial folds (NLFs) are common age-related facial lines, often treated with dermal fillers. Princess® FILLER Lidocaine (PFL; now saypha® filler Lidocaine) and Juvéderm® Ultra XC (JUXC) are both hyaluronic acid-based fillers used for this purpose. OBJECTIVES: To evaluate the effectiveness and safety of PFL in reducing NLF severity compared to JUXC using a split-face study design. METHODS: In this randomized, subject- and investigator-blinded multicenter study, subjects with moderate to severe NLFs received PFL on one side of the face and JUXC on the other. Baseline NLF severi
3. Anatomical and Histological Study of Orbital Fat and Subcutaneous Fat.
Paired human tissue analyses and nude mouse grafting experiments show orbital fat has smaller, more uniform adipocytes, denser fibrous septa, and significantly higher vascular density than abdominal subcutaneous fat. Post-transplant, orbital fat retained structure with more CD31-positive vessels and less necrosis, indicating better survival and tolerance.
Impact: Identifies anatomical-histological advantages of orbital fat that can guide donor-site selection for upper eyelid augmentation, a common aesthetic/oculoplastic need.
Clinical Implications: When correcting sunken upper eyelids, orbital fat may be preferred over subcutaneous fat due to richer vascularity and better survival after grafting, potentially improving outcomes.
Key Findings
- Orbital fat had more fibrous septa, smaller and more uniform adipocytes, and significantly higher vessel density than abdominal subcutaneous fat (p<0.05).
- After transplantation into nude mice, orbital fat retained more tissue with more CD31-positive vascular structures and less necrosis than subcutaneous fat.
- Intraoperative observation showed orbital fat is softer with a capsule and visible longitudinal vessels; subcutaneous fat was fragile and prone to oil release.
Methodological Strengths
- Paired human sampling with multimodal histology (HE, Masson) and immunofluorescence (CD31).
- In vivo validation via transplantation in nude mice with 1- and 3-month timepoints.
Limitations
- Small sample size (18 patients) and reliance on an animal model for graft outcomes.
- Quantitative volumetric retention and clinical functional outcomes were not reported.
Future Directions: Prospective clinical trials comparing volume retention and patient-reported outcomes by donor site; molecular profiling of ECM/angiogenesis; imaging-based quantification.
OBJECTIVE: Through intraoperative observation, histological analysis of specimens, and animal experiments on fat transplantation, we initially explore the histological characteristics of fat from different parts and provide theoretical support for related clinical operations. METHODS: The discarded orbital fat and subcutaneous fat tissue were collected from 18 patients who underwent upper eyelid and abdominal surgery at the same time, and 9 of them were stained with HE, Masson, and immunofluorescence to observe the histological characteristics of orbital fat and abdominal fat. The other 9 cases were transplanted to both sides of the back of 6-week-old nude mice. Samples were taken and stained 1 month and 3 months later, respectively, and the histological characteristics and fat survival after fat transplantation at different time points were observed. RESULTS: First, intraoperative observation. The orbital fat of the upper eyelid was soft, fine, and easy to stretch and shape. It had a relatively complete capsule, and more blood vessels running longitudinally from back to front could be seen on the capsule. The subcutaneous fat tissue in the abdomen was fragile and difficult to shape, and could easily break and release oil when gently pinched. There was no obvious capsule, and the adipose tissue was wrapped by loose and thin fibrous intervals into larger lobular particles. Second, tissue section staining observation. The orbital fat contained more radial fibrous intervals, forming fat lobule structures of different sizes and shapes. The adipocytes in the lobules were more uniform in shape and smaller in average diameter. They contained more small blood vessels accompanied by or interspersed with fibrous septa. The number of internal fibrous separations in subcutaneous fat was small, and the cells in the lobules were densely arranged, uneven in shape, and large in diameter; the blood vessel density per unit area was much smaller than that of orbital fat (p<0.05). Third, the general morphology of the 2 fats was observed after transplantation. Compared with subcutaneous fat, the texture of orbital fat was more pliable, the surface of the capsule was redder, and obvious blood vessels were visible. The color of subcutaneous fat was significantly yellower, and the surface of the capsule had fewer blood vessels. Fourth, histological section staining observation after fat transplantation in the 2 groups. The histological structure of the 2 grafts was similar to that before transplantation. The orbital fat graft still contained more fibrous septa and CD31-positive vascular structures, and more fat remained. However, subcutaneous fat grafts had fewer internal fibrous septa and vascular structures, and varying degrees of necrotic areas could be seen. CONCLUSIONS: Compared with subcutaneous fat tissue, the orbital fat has a more delicate texture, more fibrous intervals, a more regular shape and a smaller diameter of adipocytes, and richer blood supply. The tissue structure after orbital fat transplantation is similar to that before transplantation, and it has better survival and tolerance. These differences can be used as a basis for selecting the source of fat transplantation when correcting a sunken upper eyelid.